Q3 EPS Forecast for Axsome Therapeutics Decreased by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at William Blair dropped their Q3 2026 earnings estimates for shares of Axsome Therapeutics in a report issued on Monday, June 9th. William Blair analyst M. Minter now forecasts that the company will post earnings of $0.58 per share for the quarter, down from their previous estimate of $0.60. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics' Q4 2026 earnings at $1.20 EPS, FY2026 earnings at $1.56 EPS, FY2027 earnings at $11.43 EPS, FY2028 earnings at $22.36 EPS and FY2029 earnings at $36.22 EPS.

Several other research analysts have also commented on AXSM. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $165.00 price target (up from $160.00) on shares of Axsome Therapeutics in a report on Tuesday, May 6th. Morgan Stanley boosted their target price on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Needham & Company LLC reduced their target price on shares of Axsome Therapeutics from $153.00 to $150.00 and set a "buy" rating for the company in a research note on Monday, June 9th. HC Wainwright reissued a "buy" rating and set a $180.00 target price on shares of Axsome Therapeutics in a research note on Tuesday. Finally, Mizuho boosted their target price on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the company an "outperform" rating in a research note on Thursday, March 27th. One investment analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $172.33.

Axsome Therapeutics Stock Performance

Shares of NASDAQ AXSM traded down $2.15 during midday trading on Wednesday, hitting $104.10. The company's stock had a trading volume of 425,883 shares, compared to its average volume of 677,321. Axsome Therapeutics has a 1-year low of $72.02 and a 1-year high of $139.13. The firm's fifty day moving average price is $106.45 and its 200-day moving average price is $107.00. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The firm has a market cap of $5.13 billion, a P/E ratio of -17.38 and a beta of 0.47.

Insiders Place Their Bets

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 20,673 shares of the business's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $104.66, for a total transaction of $2,163,636.18. Following the sale, the chief operating officer now directly owns 5,783 shares in the company, valued at approximately $605,248.78. The trade was a 78.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark Coleman sold 3,750 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $105.47, for a total transaction of $395,512.50. Following the completion of the sale, the director now owns 50,387 shares in the company, valued at $5,314,316.89. The trade was a 6.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,423 shares of company stock worth $7,711,619. 22.30% of the stock is owned by corporate insiders.

Institutional Trading of Axsome Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BVF Inc. IL raised its holdings in shares of Axsome Therapeutics by 21.8% in the 1st quarter. BVF Inc. IL now owns 1,690,221 shares of the company's stock worth $197,130,000 after purchasing an additional 302,157 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Axsome Therapeutics by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 912,538 shares of the company's stock worth $77,228,000 after purchasing an additional 4,079 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Axsome Therapeutics by 23.8% in the 1st quarter. Invesco Ltd. now owns 857,001 shares of the company's stock worth $99,952,000 after purchasing an additional 164,537 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Axsome Therapeutics by 4.5% in the 1st quarter. Wellington Management Group LLP now owns 703,279 shares of the company's stock worth $82,023,000 after purchasing an additional 30,122 shares in the last quarter. Finally, Hood River Capital Management LLC raised its holdings in shares of Axsome Therapeutics by 3.2% in the 4th quarter. Hood River Capital Management LLC now owns 644,785 shares of the company's stock worth $54,555,000 after purchasing an additional 19,701 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.